Nektar Therapeutics Common Stock (NKTR)
Stock · NASDAQ · Health Care
$35.79as of 10/16/2026
Price chart
Active signals
NKTR Signal Track Record
How signals performed across all stocks →What NKTR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +4.3% | 58% | September 23, 2026 |
| Bollinger Band Breakdown | 22 | -2.8% | 45% | September 22, 2026 |
| Bollinger Band Breakout | 23 | -3.0% | 48% | August 7, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +10.6% | 75% | June 16, 2026 |
| Any 20-session window (baseline) | 0.0% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 63
- Website
- www.nektar.com/
Fundamentals
- 1-day range
- $36.94$38.74
- Market cap
- $2.48B
- P/E (trailing)
- —
- P/E (forward)
- -3.66
- EPS (trailing)
- $-6.60
- Dividend yield
- —
- Beta
- 1.34
- Avg. volume
- 1.11M
How Nektar Therapeutics Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Nektar Therapeutics Common Stock Competitors
Chosen by industry and closest market cap.
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
- PGENPrecigen Inc. Common Stock$6.39▼ 11.25%Market cap $2.47BP/E —$3.04$8.98
- KLRAKailera Therapeutics Inc. Common Stock$11.25▼ 3.93%Market cap $2.44BP/E —$9.76$28.23
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- PHVSPharvaris N.V. Ordinary Shares$27.74▼ 6.41%Market cap $2.40BP/E —$20.65$43.25
- PBHPrestige Consumer Healthcare Inc. Common Stock$49.92▲ 1.46%Market cap $2.58BP/E 13.50$42.62$71.07
- ZLABZai Lab Limited American Depositary Shares$23.19▼ 1.36%Market cap $2.35BP/E —$12.31$26.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
| PGEN Precigen Inc. Common Stock | $2.47B | — | $6.39 | ▼ 11.25% | $3.04$8.98 |
| KLRA Kailera Therapeutics Inc. Common Stock | $2.44B | — | $11.25 | ▼ 3.93% | $9.76$28.23 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| PHVS Pharvaris N.V. Ordinary Shares | $2.40B | — | $27.74 | ▼ 6.41% | $20.65$43.25 |
| PBH Prestige Consumer Healthcare Inc. Common Stock | $2.58B | 13.50 | $49.92 | ▲ 1.46% | $42.62$71.07 |
| ZLAB Zai Lab Limited American Depositary Shares | $2.35B | — | $23.19 | ▼ 1.36% | $12.31$26.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53benzinga · 10/12/2026
- BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price TargetBenzinga · 10/9/2026
- Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform RatingBenzinga · 10/9/2026
- Cedar Grove Capital Q3 2026 Portfolio UpdateSeekingAlpha · 10/7/2026
- Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year OverhangYahoo · 10/7/2026
- EADV26: Key late-stage readouts from the conferenceYahoo · 10/5/2026
- Nektar Therapeutics (NKTR) Shareholder/Analyst Call - SlideshowSeekingAlpha · 10/3/2026
- Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And MoreSeekingAlpha · 10/2/2026
- HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price TargetBenzinga · 10/2/2026
Insider Activity
Insider Actions →- WHITFIELD ROY A · September 23, 2026 · Grant4.0K
- WHITFIELD ROY A · September 23, 2026 · Grant2.0K
- Brainard Diana · September 23, 2026 · Grant4.0K
- Brainard Diana · September 23, 2026 · Grant2.0K
- Ajer Jeffrey Robert · September 23, 2026 · Grant4.0K
- Ajer Jeffrey Robert · September 23, 2026 · Grant2.0K
- CHESS ROBERT · September 23, 2026 · Grant4.0K
- CHESS ROBERT · September 23, 2026 · Grant2.0K
- GREER R SCOTT · September 23, 2026 · Grant4.0K
- GREER R SCOTT · September 23, 2026 · Grant2.0K
- Jonathan Zalevsky · August 18, 2026 · Sale186 @ $71.98
- Howard W. Robin · August 18, 2026 · Sale418 @ $71.98
- Jonathan Zalevsky · July 24, 2026 · Grant16.5K
- Howard W. Robin · July 24, 2026 · Grant57.2K
- Jonathan Zalevsky · June 30, 2026 · Sale5.7K @ $70
Institutional Ownership
March 31, 2026
- Total shares held
- 27.57M
- Total value held
- $1.94B
- Institutional holders
- 200
- Unknown4.30M
- Unknown2.56M
- Unknown1.96M
- Unknown1.20M
- Unknown930.7K
- Unknown903.2K
- Unknown735.0K
- Unknown692.6K
- Unknown665.4K
- Unknown659.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
NKTR receives mixed analyst coverage and pipeline focus
Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.
NKTR receives mixed analyst coverage and pipeline focus. Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.